Literature DB >> 35538376

Stiripentol Enteric Solid Dispersion-Loaded Effervescent Tablets: Enhanced Dissolution, Stability, and Absorption.

Ying Wang1, Siyuan Xu1, Ziyue Xiao1, Yuxin Jiang1, Qi Jiang1, Jun Li2, Wei He3.   

Abstract

Due to poor solubility and stability in acid conditions, the gastrointestinal administration of stiripentol (STP) is still a significant challenge. This study aimed to explore the applicability of effervescent tablets compressed from STP-loaded enteric solid dispersions to improve the solubility and stability of the insoluble and acid-labile drug. STP-loaded solid dispersions (STP-SDs) and the effervescent tablets (STP-SD-ETs) were prepared using solvent evaporation and dry granulation technology, respectively, and their formulations were optimized. Then, STP-SDs were characterized regarding solid state, in vitro release, stability, etc. Results showed that enteric amorphous STP-SDs were successfully prepared and significantly improved the solubility and stability of STP. Moreover, compared with STP suspensions, the bioavailability of STP-SD-ETs was as high as 138.71%. Concomitantly, STP-SD-ETs significantly increased the intestinal absorption rate of STP. Overall, the oral preparation encompassing enteric solid dispersion combined with effervescent tablet technology possesses excellent performance in enhancing dissolution, anti-acid hydrolysis stability, and absorption of STP. Our work provides a promising method to improve the delivery of drugs with poor solubility and acid-labile stability.
© 2022. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.

Entities:  

Keywords:  amorphous; effervescent tablets; epilepsy; solid dispersions; stiripentol

Mesh:

Substances:

Year:  2022        PMID: 35538376     DOI: 10.1208/s12249-022-02261-5

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  32 in total

Review 1.  Interaction of cannabidiol with other antiseizure medications: A narrative review.

Authors:  Christopher G S Gilmartin; Zoya Dowd; Alasdair P J Parker; Pooja Harijan
Journal:  Seizure       Date:  2020-10-03       Impact factor: 3.184

Review 2.  Stiripentol: A Review in Dravet Syndrome.

Authors:  James E Frampton
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

Review 3.  Dravet Syndrome: A Review of Current Management.

Authors:  James W Wheless; Stephen P Fulton; Basanagoud D Mudigoudar
Journal:  Pediatr Neurol       Date:  2020-01-31       Impact factor: 3.372

4.  Safety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome.

Authors:  Rima Nabbout; N Chemaly; C Chiron; M Kuchenbuch
Journal:  Expert Opin Drug Saf       Date:  2021-02-28       Impact factor: 4.250

Review 5.  A systematic review of adults with Dravet syndrome.

Authors:  Arunan Selvarajah; Quratulain Zulfiqar-Ali; Paula Marques; Marlene Rong; Danielle M Andrade
Journal:  Seizure       Date:  2021-02-22       Impact factor: 3.184

6.  Influence of stiripentol on perampanel serum levels.

Authors:  Nicole Trabs; Mathias Trabs; Stefan Stodieck; Patrick M House
Journal:  Epilepsy Res       Date:  2020-05-16       Impact factor: 3.045

7.  Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome.

Authors:  Marcia L Buck; Howard P Goodkin
Journal:  Ann Pharmacother       Date:  2019-06-06       Impact factor: 3.154

8.  The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results.

Authors:  Cecilie Johannessen Landmark; Heidrun Potschka; Stéphane Auvin; Jo M Wilmshurst; Svein I Johannessen; Dorothée Kasteleijn-Nolst Trenité; Elaine C Wirrell
Journal:  Epilepsia       Date:  2021-02-27       Impact factor: 5.864

9.  Stiripentol for the treatment of seizures associated with Dravet syndrome.

Authors:  Catherine Chiron
Journal:  Expert Rev Neurother       Date:  2019-04-02       Impact factor: 4.618

Review 10.  Stiripentol for the treatment of seizures in Dravet syndrome.

Authors:  Krista Eschbach; Kelly G Knupp
Journal:  Expert Rev Clin Pharmacol       Date:  2019-04-24       Impact factor: 5.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.